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Abstract
Introduction Vitiligo pathogenesis is complicated, and several possibilities were suggested. However, it is well-known that 
the metabolism of pigments plays a significant role in the pathogenicity of the disease.
Objectives We explored the role of amino acids in vitiligo using targeted metabolomics.
Methods The amino acid profile was studied in plasma using liquid chromatography. First, 22 amino acids were derivatized 
and precisely determined. Next, the concentrations of the amino acids and the molar ratios were calculated in 31 patients 
and 34 healthy individuals.
Results The differential concentrations of amino acids were analyzed and eight amino acids, i.e., cysteine, arginine, lysine, 
ornithine, proline, glutamic acid, histidine, and glycine were observed differentially. The ratios of cysteine, glutamic acid, 
and proline increased significantly in Vitiligo patients, whereas arginine, lysine, ornithine, glycine, and histidine decreased 
significantly compared to healthy individuals. Considering the percentage of skin area, we also showed that glutamic acid 
significantly has a higher amount in patients with less than 25% involvement compared to others. Finally, cysteine and lysine 
are considered promising candidates for diagnosing and developing the disorder with high accuracy (0.96).
Conclusion The findings are consistent with the previously illustrated mechanism of Vitiligo, such as production deficiency 
in melanin and an increase in immune activity and oxidative stress. Furthermore, new evidence was provided by using amino 
acids profile toward the pathogenicity of the disorder.
Keywords Vitiligo · Plasma · Metabolomics · Amino acids · Liquid chromatography
1 Introduction
Vitiligo is a common chronic skin disorder in which pig-
ment-producing cells or melanocytes are unregulated, 
resulting in varying patterns and degrees of skin depig-
mentation (Armstrong, 2011; Sahoo et  al., 2017). It is 
common, affecting 0.5–2% of the world’s population without 
preference for race or sex (Rodrigues, M., K. Ezzedine, I. 
Hamzavi, A. G. Pandya, J. E. Harris & V. W. Group, 2017). 
Diagnostically, patterns of lesions in vitiligo predict pro-
gression and treatment responses (Ezzedine et al., 2012). 
Vitiligo manifests as multiple spots appearing on the skin in 
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a symmetric pattern on both sides of the body. It may impact 
only mucosal parts of the body (mucosal vitiligo), lips or 
other parts of the face plus the hands and/or feet (acrofacial 
vitiligo), lips and fingertips (lip-tip vitiligo), only affecting 
a small area of the body (focal vitiligo), involve large parts 
of the body all over (generalized vitiligo), and most of the 
body (universal vitiligo). In addition to different anatomical 
locations on the body, there are also different appearances 
that the spots themselves can have. Four typical appearances 
include: inflammatory, trichrome, or confetti vitiligo, and 
Koebner phenomenon, indicating that the spots are more 
active in spreading. There are two main forms of vitiligo: 
segmental (unisegmental and ultisegmental) and non-seg-
mental (acrofacial, focal, mucosal, generalized, universal, 
and mixed) (Rodrigues, Ezzedine, Hamzavi, Pandya, Har-
ris, Group 2017). Segmental vitiligo does not follow normal 
rules and is distinct from all the other types listed above. It 
affects only one area of the body on only one side, without 
crossing the midline of the body on the front or back; but it 
is less common, affecting only about 5% of adults and 20% 
of children. It is rapidly progressive but stabilizes quickly, 
and is less responsive to treatment (Taïeb et al., 2007). In 
addition, it appears in non-segmental (generalized) or seg-
mental on the skin, with varying patterns, and degrees of 
skin depigmentation (Armstrong, 2011; Ding et al., 2014). 
The challenges that vitiligo sufferers face are not limited to 
cutaneous symptoms and can also be associated to a range 
of other complications.
Vitiligo is problematic due to its psychological impacts, 
which are experienced by many patients around the world 
(Grimes & Miller, 2018). The levels of hopelessness, anxi-
ety, depression, and general health of vitiligo patients have 
also been compared to normal controls in several studies 
(Hamidizadeh et al., 2020; Henning et al., 2020; Kussainova 
et al., 2020; Vernwal, 2017). Hamidizadeh et al. demon-
strated that anxiety and hopelessness levels were signifi-
cantly higher in vitiligo patients than those of healthy con-
trols. Along with social or psychological distress, people 
with vitiligo may be at increased risk of sunburn, skin can-
cer, eye problems such as inflammation of the iris (iritis) and 
hearing loss (Hamidizadeh et al., 2020; Jakku et al., 2019).
Vitiligo is an autoimmune disease of the skin that results 
in a loss of melanocytes. Intrinsic defects in melanocytes 
may initiate disease through innate inflammation. Environ-
mental factors also contribute, including exposure to phe-
nolic compounds found in household products. Nonspecific 
induction of skin inflammation may induce local vitiligo 
lesions. The interferon-ʏ -CXCL10 pathway plays a central 
role in driving autoimmunity in vitiligo (Speeckaert et al., 
2017). Genetics strongly influence the risk of developing 
disease (Seneschal et al., 2020). Genes encoding proteins 
mediating the immune response targeting melanocytes have 
been implicated in the etiology of this disease, together 
with proteins specific to these cells (Rodrigues, Ezzedine, 
Hamzavi, Pandya, Harris, Group 2017).
The etiology of vitiligo remains unclear, including the 
reasons for melanocyte death (Singh et  al., 2016). It is 
underpinned by complex immune, genetic, environmental, 
and biochemical causes, however the exact molecular mech-
anisms of its development and progression are considered 
challenging to resolve (Liang et al., 2019; Sahoo et al., 2017; 
Singh et al., 2016). Although several vitiligo susceptibil-
ity loci have been reported using genome-wide association 
studies (GWAS), a study on monozygotic twins described 
the vitiligo concordance rate as 23% and suggested a remark-
able environmental contribution to its pathogenesis (Singh, 
Lee, Vujkovic-Cvijin, Ucmak, Farahnik, Abrouk, Nakamura 
et al. 2016). Zheleva et al. revealed that oxidative stress is a 
triggering event in melanocytic destruction, which is prob-
ably involved in the enteropathogenesis of vitiligo disease. 
Oxidative stress biomarkers could be found in the skin 
and blood of vitiligo patients (Zheleva et al., 2018). Sahoo 
et al. reported that a human vitiligo cell line and PIG3V 
have unique lipid profiles, which are potentially associated 
with vitiligo activity in skin and blood. These profiles con-
tain some biomarker candidates for determining treatment 
response and progressing the disease earlier and accurately 
(Sahoo, Lee, Boniface, Seneschal, Sahoo, Seki, Wang et al. 
2017). Key proteins involved in vitiligo were surveyed for 
their molecular connectivity and topological parameters to 
identify causative factors in vitiligo. A comprehensive viti-
ligo map with 4845 protein nodes linked with 107,416 edges 
revealed a list of top-order proteins that play a key role in 
the disease pathology mechanism including SUMO2, ESR1, 
COPS5, MYC, SMAD3, and Cullin proteins (Malhotra et al., 
2018). The need for a useful non-invasive tool for large-scale 
screening, urinary metabolomics was recently reported to 
detect disease-related metabolites using (Liu et al., 2020).
The role of other small molecules in vitiligo, such as 
amino acids, remains unanswered. In general, amino acids 
play an essential role in detoxification and immune responses 
through regulating the activation of T and B lymphocytes, 
natural killer cells, macrophages, and cellular redox state 
(Li, Yin, Li, Kim, Wu 2007). However, there is currently a 
dearth of comprehensive amino acid screening in vitiligo. 
Here, using metabolomics approach to assess global low 
molecular weight metabolites, we provide insights into the 
driving mechanisms of vitiligo and propose more potential 
biomarkers (Liang et al., 2019; Speeckaert et al., 2017). Our 
research focuses on establishing whether levels of important 
substrates, such as amino acids, are the most important pri-
mary metabolites altered in the plasma of vitiligo patients. 
Thus, these molecules may contribute to the vitiligo pheno-
type in melanocytes. In the present study we sought to evalu-
ate a comprehensive profile of amino acids in the plasma of 
people with vitiligo compared to healthy people in order to 
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find a fast-determinable potential biomarker, identify pos-
sible therapeutic target candidates, and to explore pathogenic 
pathways.
2  Material and methods
2.1  Patient samples
The study was undertaken according to the Helsinki Dec-
laration and approved by the ethical review board of the 
Shahid Beheshti University of Medical Science with writ-
ten and signed informed consent from the study subjects. 
Table 1 demonstrates patient and healthy individual data. 
Altogether 31 cases with vitiligo patients and 34 healthy 
individuals attended the dermatology clinic of Shohadaye 
Tajrish Hospital (Jun–Dec 2018). Vitiligo diagnosis was 
based on the characteristic loss of skin pigmentation and 
examination under a Wood's lamp. Plasma (with K2‐EDTA) 
was immediately separated from the peripheral venous blood 
by centrifugation at 1792 g at 4 °C for 20 min. The super-
natant was isolated, snap-frozen, and stored at − 80 °C until 
analysis.
2.2  Amino acid analysis
To prepare the samples they were transferred from the 
− 80 °C freezer and placed on ice to be melted. To 50 
µL of sample, 20 µL norleucine (500 μM) and 200 µL 
of methanol (kept at − 20 °C) were added and all are 
mixed for five seconds. To completely deproteinate, sam-
ples were kept at − 20 °C for 2 h, then centrifuged at 
19,000 g for 12 min at 4 °C. The entire supernatant was 
transferred to a Heidolph rotary evaporator and dried in 
a vacuum. These samples could be stored at 4 °C for four 
weeks. For HPLC analysis, previously dried samples were 
dissolved in 100 µl of water (containing 0.01% formic 
acid). According to a previously described derivatization 
strategy, 10 µL o-phthaldialdehyde (OPA,) (for derivati-
zation of primary amino acids) and 10 µL fluoronylme-
thyl chloroformate (FMOC-Cl) (for secondary amino acid 
derivatization) were added to 10 µl of each sample, and 20 
µL of this was then injected into the HPLC system (Fek-
kes, 2012; Wu et al., 2016). For the HPLC–DAD method, 
a Knauer system (WellChrom, Germany) equipped with a 
K-1001 pump, a K-2800 diode array detector, an autosa-
mpler S3900 (Midas), a K-5004 analytical degasser, and 
a 2301 Rheodyneinjector with a 20 µL loop was used. 
HPLC separation was achieved using a Eurospher C18 
column (4.6 mm × 250 mm, 5 µm), with a gradient elution 
program at a flow rate of 1.0 ml  min−1. The mobile phase 
was composed of solution A (acetonitrile + 0.05% trif-
luoroacetic acid, v/v) and solution B (0.05% aqueous tri-
fluoroacetic acid, v/v). Then, the following gradient was 
applied: 0–10 min, isocratic gradient 70% B; 10–30 min, 
linear gradient 70–40% B; 30–40 min, linear 40–20% B; 
40–50 min, linear 20–0% B; 50–65 min, linear 0–70% 
B; 65–75 min, isocratic gradient 70% B. The chromato-
graphic peaks of the sample solution were identified by 
spiking and comparing their retention times and UV spec-
tra with those of reference standards. Quantitative analy-
sis was carried out by integration of the peak using the 
standard external method. To detect primary amino acids, 
the fluorescence detector was set at 337 nm and 470 nm 
for adsorption and excitation, respectively. Also, detec-
tion of the first-type and the second-type amino acids was 
performed at 262 nm and 338 nm. The instrument stabil-
ity of the analyses was checked during the study using 
quality control samples (QCs), a pool of all samples. 
This pool was prepared through mixing equal volumes 
of all samples and stored in 100 µl aliquots to avoid the 
repeated freeze–thaw cycles. A QC sample was injected 
in every six samples after being prepared under the same 
conditions. Measurement variability was assessed by cal-
culating CVs based on QCs. All 22 amino acids showed 
acceptable repeatability with CVs < 10% in QCs. Also, as 
mentioned, the accuracy and precision of both derivatiza-
tion and HPLC technique were performed using analyzing 
of five individual samples. The intra-day mean coefficient 
of variation (n = 3) and the inter-day mean coefficient of 
variation (n = 3) were within 2% and 7%, respectively.
2.3  Statistical methods
We utilized R version 4.0.0 (https:// www.r- proje ct. org/) for 
our statistical study. The data was transformed into Log2 
format before to the investigation. The Shapiro–Wilk test 
was used to check for normal distribution in the data. We 
used non-parametric approaches since the data were not nor-
mally distributed. To compare study groups, we employed 
the Mann Whitney U Test (Wilcoxon Rank Sum Test) with 
Table 1  Demographics of the study cohort




Age, years** 35.8 ± 11.9 34.96 ± 11.59
Duration of the disease (year) – 10.8 ± 9.5
Illness severity (body surface area 
involvement %)
– 32.41 ± 22.18
Active disease (having new lesions 
during last 6 months)
– 23
Positive family history – 24
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the BH (Benjamini Hochberg) correction (Mohieddin and 
Naser, 2019). We also used principal component analysis to 
gauge sample homogeneity (PCA). The importance of ran-
dom forest features (mean Gini reduction) for the response 
variable was calculated to determine the difference between 
two groups. The confusion matrix was then calculated using 
the results of the random forest classification. We employed 
logistic regression and sensitivity analysis via the receiver 
operating characteristic (ROC) curve to examine the signifi-
cantly different amino acids that we picked as biomarkers for 
the cause likelihood or severity of the disease. The Mann 
Whitney U test with BH correction was also used to compare 
the two groups of patients and healthy people by evaluating 
the link between disease severity, disease progression, and 
family history, with the amino acid profile. Furthermore, to 
explore the association of amino acids with disease progres-
sion, we divided vitiligo patients into two groups based on 
the percentages of skin involvement area. The 25% cut-off 
was chosen after evaluating a series of cut-offs using differ-
ential analysis of amino acid profiles. Therefore, the patients 
showing symptoms on more and less than 25% of their body 
skin surface area were categorized as progressive and benign 
vitiligo patients, respectively.
3  Results
3.1  Targeted metabolomic analysis of plasma 
reveals vitiligo‐specific biomarker profiles
We performed targeted quantitative analysis of 22 amino 
acids on the plasma of patients with vitiligo disorders. All 
samples from the patient and control groups (34 healthy 
cases and 31 vitiligo cases) were analyzed by principal com-
ponent analysis (PCA). The samples were well-clustered in 
two separate groups (Fig. 1). Supplementary file 1 shows 
the absolute concentration of 22 amino acids in both groups.
Next, the data were analyzed to find the difference in 
amino acid concentrations in both groups (Supplementary 
file 1 and 2). Figure 2a demonstrates a volcano graph in 
which horizontal and vertical axes correspond to log2 fold 
change of sample concentrations and −  log10 adjusted 
p-values, respectively. The Wilcox rank test revealed a more 
than twofold elevation in Cysteine, Proline, and Glutamic 
acid levels with a p-value less than 0.05. In addition, lysine, 
arginine, ornithine, histidine, and glycine decreased by half 
or less in vitiligo patients (Supplementary file 2). Figure 2b 
shows the Gini error reduction diagram obtained from the 
random forest algorithm with a tree number of 500. In this 
plot, a higher mean decrease in Gini indicates higher amino 
acid importance. Amino acids are sorted and displayed in 
this plot based on the Gini index. Cysteine showed the high-
est Gini index with a high amount in vitiligo samples. Lysine 
and arginine were in the second and third rank of this plot 
with a high amount in healthy individuals.
The performance of amino acids was then tested as dis-
ease biomarkers in a pooled set of vitiligo patients, to deter-
mine which amino acids would demonstrate the best sen-
sitivity and specificity for vitiligo to be distinguished from 
healthy controls. Based on receiver operating characteristic 
(ROC) curve analysis, the top two significant amino acids 
with the highest area under the curve (AUC) were cysteine 
and lysine with 0.91 AUC independently and 0.96 AUC 
together, called “multi‐biomarker” for vitiligo (Fig. 3a & b). 
A positive/negative coefficient means the role of the amino 
acids in increasing or decreasing the risk of vitiligo. Next, 
based on the random forest method, a confusion matrix was 
developed in which two groups used in the present study 
were classified with a low amount of classification error 
(0.032) (Fig. 3c).
3.2  Glutamic acid as biomarker for Vitiligo 
progressing
The role of amino acids in developing vitiligo was evaluated 
based on the size of skin involvement area. As a result, the 
proportion of vitiligo-affected skin compared to the total 
body area was utilized to assess any differences in amino 
acid amounts across multiple cut-offs. Glutamic acid had a 
lower amount by using 25% as a cut-off after comparing the 
patients with more and less than 25% involvement. It seems 
that glutamic acid becomes involved in developing vitiligo 
while it cannot contribute to vitiligo progress at a severe 
stage. The amount of glutamic acid decreased significantly 
for the patients with more than 25% involvement, similar to 
Fig. 1  PCA analysis of data obtained by HPLC-FLD. All 22 amino 
acid concentrations were used to evaluate the sample homogeneity as 
a quality assessment of this study
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healthy individuals (Figs. 4a &b). It is worth noting that no 
other remarkable changes occurred in the amount of amino 
acids by considering a serial of cut-offs for skin involvement 
percentages.
Glutamate is easily the most abundant transmitter in the 
nervous system and is reported to be the neurotransmitter at 
40% of all synapses in the brain (Binder et al., 2009). There-
fore, if neuron fails to respond to glutamate, it is either not a 
neuron or it is dead. Glutamic acid decarboxylase (GAD) is 
an autoantigen in vitiligo and correlates with glutamic acid. 
Antibodies to GAD are frequently found in patients suffering 
autoimmune symptoms (Klemetti et al., 2000). This supports 
the critical role that glutamic acid may play in autoimmune 
diseases such as vitiligo.
3.3  Pathway analysis: Amino acid metabolism 
remodeled in melanin production
Pathway analysis of plasma amino acids showed several 
significantly changed pathways common to all vitiligo 
patients, but not to healthy individuals (Fig. 5). Pathway-
associated metabolite and disease-associated metabolite 
analyses were performed to demonstrate the significantly 
altered metabolic pathways in Vitiligo cases. Based on the 
findings, 35 pathways were significantly different between 
Vitiligo and healthy samples, of which some pathways 
showed high fold enrichment values. Metabolites and meta-
bolic terms changed in Vitiligo cases with lower p-values 
and higher fold enrichment values, including: arginine and 
proline metabolism, glycine and serine metabolism, glu-
tathione metabolism, urea cycle, ammonia recycling, gluta-
mate metabolism, alanine metabolism, carnitine synthesis, 
Fig. 2  a Volcano plot of amino acid plasma concentration, b Gini 
error reduction diagram with tree number of 500, and notched box 
plot for increased c and decreased d amino acids. The red and blue 
dots indicate amino acid values  in healthy individuals (control) and 
vitiligo patients, respectively. The adjusted p-values  are represented 
in these plots
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cysteine metabolism, lysine degradation, beta-alanine 
metabolism, aspartate metabolism, and methyl histidine 
metabolism. After disease-based enrichment analysis, 
disease-associated metabolite terms were observed for viti-
ligo patients compared to healthy controls. Ornithine tran-
scarbamylase deficiency (OTC), Hyperornithinemia with 
Fig. 3  a ROC curve for Cysteine and Lysine with the highest vari-
ations, b ROC curve to show the sensitivity and specificity of the 
eight top amino acids, i.e. Cys, Lys, Tyr, Orn, Pro, Glu, Leu, and Gly 
independently with the AUC (Area under curve) values c confusion 
matrix based on random forest model
Fig. 4  Amino acid amount analysis of patients with more and less 
than 25% of skin involvement area. a Volcano diagram shows the 
amount fold changes of all amino acids with adjusted p-values. b The 
notched box plots indicate the amount of glutamic acid in patients 
compared to healthy individuals
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gyrate atrophy (HOGA), Delta-pyrrolidone-5-carboxylate 
synthase, hyperprolinemia-type II, short bowel syndrome 
(under arginine -free), 2-hydroxyglutaric acidemia, 3-phos-
phoglycerate dehydrogenase deficiency dementia, dicarbo-
xylic aminoaciduria, histidinemia, hyperlysinemia I-Family 
I, phosphoserine aminotransferase deficiency, short-bowel 
syndrome, and SOTOS syndrome are considered to be sig-
nificant disease-associated metabolic diseases with high 
amounts of fold enrichment values.
4  Discussion
The present study focused on disease‐specific amino acid 
fingerprints, which were detectable in the plasma of patients 
suffering from vitiligo, an asymptomatic disorder resulting 
from losing melanin. The disease group showed plasma 
amino acid fingerprints which were separately clustered 
from healthy controls, indicating the potential of amino acid 
fingerprints as multi‐biomarkers for diagnosis, disease pro-
gression follow-up, and possible treatment effect. Patients 
with skin involvement area more than 25% displayed similar 
amino acid changes reflected in plasma by providing more 
details about the role of amino acids in progressing the dis-
ease. Furthermore, the targeted metabolomics approach 
identified known therapy targets, already in clinical use, 
and identified new potential targets for treating vitiligo. 
Thus, targeted metabolomic analysis may be not only valu-
able for mechanistic studies, but also for metabolic targets 
in treatment trials. Amino acids play important roles in both 
mental and physical functions as regulators of metabolism, 
nutrients, neurotransmitters, and neuromodulators. There are 
many reports profiling amino acids to discovering biomark-
ers (Simińska & Koba, 2016). In previous studies of the 
metabolite and protein profiles of patients with vitiligo, the 
expression of several metabolites and proteins involved in 
the immune system were checked. Among these metabo-
lites and proteins, lysophosphatidylcholine, platelet-acti-
vating factor, sn-glycerol-3-phosphocholine, succinic acid, 
CXCL4, and CXCL7 were significantly elevated in the 
plasma of patients with vitiligo. Interestingly, aspartate was 
downregulated and glutamic acid was upregulated (Liang 
et al., 2019). To the best of our knowledge, few studies have 
investigated the role of some amino acids and the derivative 
molecules associated with the melanin production in vitiligo 
such as phenylalanine, tyrosine and glucosamine, trimethyl-
amine, cysteine, homocysteine, and thiol (Roy, 2007; Sahoo, 
Lee, Boniface, Seneschal, Sahoo, Seki, Wang et al. 2017). 
Based on these observations, there are both conventional and 
unconventional potential therapies for vitiligo, including: (i) 
amino acids such as L-phenylalanine; (ii) antioxidant agents 
such as alpha lipoic acid, glutathione (GSH), fluorouracil, 
levamisole, and melagenine; and (iii) metals such as zinc, 
minoxidil (Gianfaldoni et al., 2018).
Fig. 5  Pathway-associated and disease-associated metabolite analyses. The colored bars are based on P values, and the bar length corresponds to 
the fold enrichment. The corrected P values are provided
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However, we first provided the complete profile of free 
amino acids in plasma to evaluate the changes in the meta-
bolic pathways of vitiligo. We found that arginine and pro-
line metabolism are the most significant pathway enriched 
based on the altered amino acid profile in vitiligo. In most 
cell types, arginine, as a precursor of citrulline, regulates 
the activity of the immune system by producing nitric 
oxide (Rath et al., 2014). It is increasingly clear that proline 
metabolism plays an important role in metabolic reprogram-
ming. Although first focused on proline catabolism, recent 
studies from a number of laboratories have emphasized the 
regulatory effects of proline synthesis and proline cycling. 
On the other hand, pyrroline-5-carboxylate dehydrogenase 
(P5CDH) is localized to the mitochondria and is critical in 
the anaplerotic role of proline released from proteins, for 
example, collagen (Phang, 2019). On the other hand, orni-
thine is catabolized by proline oxidase in different organs 
to produce hydrogen peroxide and pyrroline-5-carboxylate 
(P5C). By converting P5C into proline, a reduction occurs 
in the ratio of NADP + to P5C reductase-dependent NADPH 
(Abumrad & Barbul, 2004; Bansal & Ochoa, 2003; Flynn 
et al., 2002; Rath et al., 2014; Wu et al., 2005, 2011). Addi-
tionally, the proline-P5C cycle regulates the cellular redox 
state. These products have well-known functions, such as 
mitochondrial integrity, ion channel activity, cell death, anti-
oxidation, and anti-tumor activity. Additionally, arginine and 
ornithine decreased and proline increased at the same time 
in patients. Thus, the findings indicated impaired arginine 
and proline metabolism, urea cycle, or nitrogen imbalance 
due to mitochondrial deficiencies in vitiligo. In other words, 
it is a consequence of a disruption in response to oxida-
tive stress and cell damage. The amount of glycine in viti-
ligo was also lower than that of healthy controls. Glycine 
itself is considered as a potent antioxidant scavenging free 
radical, which is essential for the antioxidative defense of 
leukocytes. Furthermore, it plays a major role as an anti-
inflammatory, immunomodulatory, and cytoprotective agent. 
Therefore, glycine reduction in patients strengthens the pre-
viously proposed association of developing vitiligo with the 
oxidative stress response. On the other hand, lysine, which 
decreases in vitiligo patients, has multiple catabolic path-
ways, such as carnitine biosynthesis. Carnitine and its esters 
help reduce oxidative stress (Pekala et al., 2011). Therefore, 
the reduction of this amino acid highlights the role of oxida-
tive stress in vitiligo.
Additionally, glutamic acid increased in the patient group 
compared to the healthy control. It means that we can expect 
the increased activity of the immune system and the cellular 
redox state. Glutamic acid paves the way for transporting 
the reducing agents across the mitochondrial membrane and 
regulating glycolysis and cellular redox state through the 
malate/aspartate shuttle (Mori, 2007). In the present study, 
a high amount of cysteine was observed in vitiligo patients, 
which is the downstream product of homocysteine. Some 
studies indicated a high amount of homocysteine and thiols 
in vitiligo patients, and predicted the cysteine increment in 
this disease accordingly (Agarwal et al., 2015; Akoglu et al., 
2018; Hamza et al., 2015; Sabry et al., 2014; Shaker & El-
Tahlawi, 2008; Singh et al., 2011, 2016).
Tyrosine metabolism was also enriched in vitiligo 
patients. Tyrosine is converted into dopaquinone, as a highly 
intermediary metabolite, which is essential for regulating 
melanogenesis. Dopaquinone, in a rapid reaction with 
cysteine, becomes involved in pheomelanin production, 
which is considered a common melanin pigment found in 
hair and skin color (Ito et al., 2000). Likewise, we detected 
a high level of cysteine in the patients, indicating that the 
production of pheomelanin pigment is impaired by other 
factors, such as increasing thiol levels. Based on the find-
ings, cysteine and the ratio of cysteine to ornithine increased 
along with a decrease in the ratio of glycine, arginine, orni-
thine, and lysine to cysteine in the patient group (Fig. 2 & 
Supplementary file 2). Thus, impaired cysteine metabolism 
disrupts the production of pigment, increases the activity 
of the immune system, and might counteract the effects of 
oxidative stress due to a deficiency in the production of anti-
oxidant compounds.
Moreover, histidine was also significantly lower in the 
patient group. This amino acid plays a vital role in the skin 
vulnerability to the UV as an upstream molecule to make 
urocanic acid. In other words, histidine controls the activ-
ity of immune system against the UV radiation from the 
sun (Fabo & Noonan, 1983; Fabo et al., 1997; Gibbs et al., 
2008); Hence, the reduced amount of histidine in vitiligo 
indicates a disturbance of the skin immune system, empha-
sizing the necessity of vitiligo patients to protect themselves 
against UV.
In the present study, glutamic acid was considered as a 
potential biomarker for progressing the disease. In addition, 
it can help determine 25% involvement of skin area as a 
candidate cut-off to divide patients into early and late stages 
of vitiligo. Furthermore, glutamic acid demonstrated a pulse 
propagation behavior by increasing the spot extent across the 
body surface. Due to the role of glutamate in regulating the 
cell cycle (Coloff et al., 2016; Murakami et al., 2012; News-
holme et al., 2003), its altering level in vitiligo can indicate 
implicated cell metabolism and increased cell death. On the 
other hand, some studies previously reported the influence 
of glutamate imbalance through glutamatergic neurotrans-
mission with anxiety and stress (Amiel & Mathew, 2007; 
Bergink et al., 2004; Cortese & Phan, 2005). Our findings 
indicated that glutamate also engaged in this prevalent psy-
chiatric disorder in patients, which has been described in 
vitiligo frequently (Hamidizadeh et al., 2020; Henning, 
2020; Kussainova et al., 2020; Vernwal, 2017).
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Interestingly, as shown in Table 1, 65% of the studied 
population has a positive family history. Vitiligo is a com-
plex disorder (also termed polygenic and multifactorial), 
reflecting simultaneous contributions of multiple genetic 
risk factors and environmental triggers. Genetics influ-
ence the risk of developing disease (Seneschal et al., 2020). 
Early clinical case series reported a frequency of vitiligo in 
probands’ relatives of 11–38% (Spritz & Andersen, 2017). 
Also, there are some reports suggesting a polygenic, multi-
factorial mode of inheritance, and estimated vitiligo herit-
ability at 46–72% (Hafez & Sharaf, 1983). Altogether the 
65% of the studied population affected by vitiligo could be a 
consequence of both factors, including genetics and lifestyle.
5  Conclusion
Based on the results of the present and previous studies on 
vitiligo, melanin production decreased by increasing the 
amount of cysteine and disrupted oxidative stress based on 
the glutamic acid and proline enhancement. Moreover, the 
reduction of arginine, glycine, lysine, histidine, and ornith-
ine can damage melanocytes. They resulted in vitiliginous 
lesions on the skin surface of patients. This finding demon-
strated the importance of these pathways either causing, or 
as a consequence of, vitiligo. Thus, examining the proposed 
biomarkers can contribute to the early diagnosis of at-risk 
patients. Additionally, considering the changes in glutamic 
acid levels as biomarkers can help determine the progno-
sis of the disease. In-depth understanding of the role of 
these biomarkers in vitiligo can provide the scientific basis 
for developing innovative therapeutic approaches for this 
disorder.
In the present study, separate patients were clustered 
based on their age‐ and gender‐matched controls in this 
targeted metabolomic analysis. The results highlight the 
potential of this approach for mechanistic studies and as 
biomarkers for disease progression follow-up. Despite the 
fact that our screening on amino acid targets corroborated 
previously examined metabolite targets for vitiligo disease 
and proposed new ones, these differential profiles would be 
best investigated at the localized tissue-level, which is the 
current study's limitation.
Supplementary Information The online version contains supplemen-
tary material available at https:// doi. org/ 10. 1007/ s11306- 021- 01843-x
Acknowledgements The authors gratefully acknowledge the financial 
support of Shahid Beheshti University, Tehran, Iran. Also, this study 
was financially supported by the Academy of Finland (No. 332454).
Authors contribution Participated in research design: MM, MK, HR 
and MJ. Conducted experiments: RM, SK, NM, and HR. Contributed 
new reagents or analytic tools: MM, HR, and MJ. Performed data 
analysis: RM, PC, SK, HR, MM, AN and MJ. Wrote or contributed to 
the writing of the manuscript: RM, PC, AN, and MJ.
Funding Open access funding provided by University of Helsinki 
including Helsinki University Central Hospital.
Data availability Raw metabolite profiles and corresponding metadata 
are available from the MetaboLights repository (Haug et al. 2020) 
under the accession number MTBLS3462 (www. ebi. ac. uk/ metab oligh 
ts/ MTBLS 3462).
Declarations 
Conflict of interest The authors declare no conflict of interest.
Open Access This article is licensed under a Creative Commons Attri-
bution 4.0 International License, which permits use, sharing, adapta-
tion, distribution and reproduction in any medium or format, as long 
as you give appropriate credit to the original author(s) and the source, 
provide a link to the Creative Commons licence, and indicate if changes 
were made. The images or other third party material in this article are 
included in the article's Creative Commons licence, unless indicated 
otherwise in a credit line to the material. If material is not included in 
the article's Creative Commons licence and your intended use is not 
permitted by statutory regulation or exceeds the permitted use, you will 
need to obtain permission directly from the copyright holder. To view a 
copy of this licence, visit http:// creat iveco mmons. org/ licen ses/ by/4. 0/.
References
Abumrad, N., A. Barbul (2004). The use of arginine in clinical prac-
tice. Metabolic and therapeutic aspects of amino acids in clini-
cal nutrition, 595–611
Agarwal, S., Mendiratta, V., Chander, R., Jain, A., & Yadav, P. 
(2015). Study of serum levels of Vitamin B12, folic acid, and 
homocysteine in vitiligo. Pigment International, 2, 76.
Akoglu, G., Neselioglu, S., Karaismailoglu, E., Aktas, A., & Erel, O. 
(2018). Plasma thiol levels are associated with disease severity 
in nonsegmental vitiligo. Indian Journal of Dermatology, 63, 
323.
Amiel, J. M., & Mathew, S. J. (2007). Glutamate and anxiety disorders. 
Current Psychiatry Reports, 9, 278–283. https:// doi. org/ 10. 1007/ 
s11920- 007- 0033-7
Armstrong, A. (2011). Advances in Malignant Melanoma: Clinical and 
Research Perspectives, BoD–Books on Demand.
Bansal, V., & Ochoa, J. B. (2003). Arginine availability, arginase, and 
the immune response. Current Opinion in Clinical Nutrition & 
Metabolic Care, 6, 223–228.
Bergink, V., van Megen, H. J. G. M., & Westenberg, H. G. M. (2004). 
Glutamate and anxiety. European Neuropsychopharmacology, 14, 
175–183. https:// doi. org/ 10. 1016/ S0924- 977X(03) 00100-7
Binder, M. D., Hirokawa, N., & Windhorst, U. (2009). Encyclopedia 
of neuroscience (Vol. 3166). Springer.
Coloff, J. L., et al. (2016). Differential glutamate metabolism in prolif-
erating and quiescent mammary epithelial cells. Cell Metabolism, 
23, 867–880.
Cortese, B. M., & Phan, K. L. (2005). The role of glutamate in anxiety 
and related disorders. CNS Spectrums, 10, 820–830. https:// doi. 
org/ 10. 1017/ s1092 85290 00104 27
 R. Marzabani et al.
1 3
  92  Page 10 of 11
De Fabo, E. C., & Noonan, F. P. (1983). Mechanism of immune sup-
pression by ultraviolet irradiation in vivo. I. Evidence for the 
existence of a unique photoreceptor in skin and its role in pho-
toimmunology. Journal of Experimental Medicine, 158, 84–98.
De Fabo, E. C., Webber, L. J., Ulman, E. A., & Broemeling, L. D. 
(1997). Dietary L-histidine regulates murine skin levels of trans-
urocanic acid, an immune-regulating photoreceptor, with an 
unanticipated modulation: Potential relevance to skin cancer. The 
Journal of Nutrition, 127, 2158–2164.
Ding, X., Du, J., & Zhang, J. (2014). The Epidemiology and Treat-
ment of Vitiligo: A Chinese Perspective. Pigmentary Disorders, 
1(2376–0427), 1000148.
Ezzedine, K., et al. (2012). Revised classification/nomenclature of 
vitiligo and related issues: The Vitiligo Global Issues Consensus 
Conference. Pigment Cell & Melanoma Research, 25, E1–E13.
Fekkes, D. (2012). Automated analysis of primary amino acids in 
plasma by high-performance liquid chromatography Amino Acid 
Analysis.(pp183–200). Springer.
Flynn, N., Meininger, C., Haynes, T., & Wu, G. (2002). The metabolic 
basis of arginine nutrition and pharmacotherapy. Biomedicine & 
Pharmacotherapy, 56, 427–438.
Gianfaldoni, S., et al. (2018). Unconventional treatments for Vitiligo: 
Are they (Un) satisfactory? Open Access Macedonian Journal of 
Medical Sciences, 6, 170.
Gibbs, N. K., Tye, J., & Norval, M. (2008). Recent advances in uro-
canic acid photochemistry, photobiology and photoimmunology. 
Photochemical & Photobiological Sciences, 7, 655–667.
Grimes, P., & Miller, M. (2018). Vitiligo: Patient stories, self-esteem, 
and the psychological burden of disease. International Journal of 
Women’s Dermatology, 4, 32–37.
Hafez, M., & Sharaf, L. (1983). The genetics of vitiligo. Acta Dermato-
Venereologica, 63, 249–251.
Hamidizadeh, N., Ranjbar, S., Ghanizadeh, A., Parvizi, M. M., Jafari, 
P., & Handjani, F. (2020). Evaluating prevalence of depression, 
anxiety and hopelessness in patients with Vitiligo on an Iranian 
population. Health and Quality of Life Outcomes, 18, 20.
Hamza, A. M., Farid, C. I., El-sayed, E. T., & Kadeeb, H. A. (2015). 
Assessment of serum homocysteine level in patients with nonseg-
mental vitiligo. Egyptian Journal of Dermatology and Venerol-
ogy, 35, 59.
Haug, K., et al. (2020). MetaboLights: A resource evolving in response 
to the needs of its scientific community. Nucleic Acids Research, 
48, D440-d444. https:// doi. org/ 10. 1093/ nar/ gkz10 19
Henning, S. W., et al. (2020). The relationship between stress and viti-
ligo: Evaluating perceived stress and electronic medical record 
data. PLoS ONE, 15, e0227909.
Ito, S., Wakamatsu, K., & Ozeki, H. (2000). Chemical analysis of mela-
nins and its application to the study of the regulation of melano-
genesis. Pigment Cell Research, 13, 103–109.
Jakku, R., Thappatla, V., Kola, T., & Kadarla, R. K. (2019). VITI-
LIGO-An Overview. Asian Journal of Pharmaceutical Research 
and Development, 7, 124–132.
Klemetti, P., et al. (2000). Autoimmunity to glutamic acid decarboxy-
lase in patients with autoimmune polyendocrinopathy–candidi-
asis–ectodermal dystrophy (APECED). Clinical & Experimental 
Immunology: Endocrine Disease, 119, 419–425.
Kussainova, A., et al. (2020). Vitiligo and anxiety: A systematic review 
and meta-analysis. PLoS ONE, 15, e0241445. https:// doi. org/ 10. 
1371/ journ al. pone. 02414 45
Liang, L., Li, Y., Tian, X., Zhou, J., & Zhong, L. (2019). Compre-
hensive lipidomic, metabolomic and proteomic profiling reveals 
the role of immune system in vitiligo. Clinical and Experimental 
Dermatology, 44, e216–e223.
Liu, W., et al. (2020). Urinary metabolomic investigations in vitiligo 
patients. Scientific Reports, 10, 1–11.
Malhotra, A. G., Jha, M., Singh, S., & Pandey, K. M. (2018). Con-
struction of a comprehensive protein–protein interaction map for 
vitiligo disease to identify key regulatory elements: A systemic 
approach. Interdisciplinary Sciences: Computational Life Sci-
ences, 10, 500–514.
Mori, M. (2007). Regulation of nitric oxide synthesis and apoptosis by 
arginase and arginine recycling. The Journal of Nutrition, 137, 
1616S-1620S.
Murakami, H., Shimbo, K., Inoue, Y., Takino, Y., & Kobayashi, H. 
(2012). Importance of amino acid composition to improve skin 
collagen protein synthesis rates in UV-irradiated mice. Amino 
Acids, 42, 2481–2489.
Newsholme, P., Procopio, J., Lima, M. M. R., Pithon-Curi, T. C., & 
Curi, R. (2003). Glutamine and glutamate—their central role in 
cell metabolism and function. Cell Biochemistry and Function, 
21, 1–9.
Pekala, J., et al. (2011). L-carnitine-metabolic functions and meaning 
in humans life. Current Drug Metabolism, 12, 667–678.
Phang, J. M. (2019). Proline metabolism in cell regulation and cancer 
biology: Recent advances and hypotheses. Antioxidants & Redox 
Signaling, 30, 635–649.
Rath, M., Müller, I., Kropf, P., Closs, E. I., & Munder, M. (2014). 
Metabolism via arginase or nitric oxide synthase: Two compet-
ing arginine pathways in macrophages. Frontiers in Immunology, 
5, 532.
Rodrigues, M., K. Ezzedine, I. Hamzavi, A. G. Pandya, J. E. Harris, 
V. W. Group. (2017). New discoveries in the pathogenesis and 
classification of vitiligo. Journal of the American Academy of 
Dermatology, 77, 1–13.
Roy, S. (2007). Melanin, melanogenesis, and vitiligo Progress in the 
Chemistry of Organic Natural Products.(pp131–185). Springer.
Sabry, H. H., Sabry, J. H., & Hashim, H. M. (2014). Serum levels of 
homocysteine, vitamin B12, and folic acid in vitiligo. Egyptian 
Journal of Dermatology and Venerology, 34, 65–69.
Sahoo, A., et al. (2017). MicroRNA-211 regulates oxidative phospho-
rylation and energy metabolism in human vitiligo. Journal of 
Investigative Dermatology, 137, 1965–1974.
Seneschal, J., K. Boniface, A. D’Arino, M. Picardo (2020). An update 
on Vitiligo pathogenesis. Pigment cell & melanoma research,
Shaker, O., & El-Tahlawi, S. (2008). Is there a relationship between 
homocysteine and vitiligo? A pilot study. British Journal of Der-
matology, 159, 720–724.
Simińska, E., & Koba, M. (2016). Amino acid profiling as a method 
of discovering biomarkers for early diagnosis of cancer. Amino 
Acids, 48, 1339–1345.
Singh, R. K., et al. (2016). The role of IL-17 in vitiligo: A review. 
Autoimmunity Reviews, 15, 397–404.
Singh, S., Singh, U., & Pandey, S. S. (2011). Increased level of serum 
homocysteine in vitiligo. Journal of Clinical Laboratory Analysis, 
25, 110–112.
Speeckaert, R., Speeckaert, M., De Schepper, S., & van Geel, N. 
(2017). Biomarkers of disease activity in vitiligo: A systematic 
review. Autoimmunity Reviews, 16, 937–945.
Spritz, R. A., & Andersen, G. H. (2017). Genetics of vitiligo. Derma-
tologic Clinics, 35, 245–255.
Taïeb, A., Picardo, M., & o. V. members, . (2007). The definition and 
assessment of vitiligo: A consensus report of the Vitiligo Euro-
pean Task Force. Pigment Cell Research, 20, 27–35.
Vernwal, D. (2017). A study of anxiety and depression in Vitiligo 
patients: New challenges to treat. European Psychiatry, 41, 
S321–S321.
Wu, G., et  al. (2011). Proline and hydroxyproline metabolism: 
Implications for animal and human nutrition. Amino Acids, 40, 
1053–1063.
Metabolomic signature of amino acids in plasma of patients with non-segmental Vitiligo 
1 3
Page 11 of 11    92 
Wu, G., Bazer, F. W., Hu, J., Johnson, G. A., & Spencer, T. E. (2005). 
Polyamine synthesis from proline in the developing porcine pla-
centa. Biology of Reproduction, 72, 842–850.
Wu, J.-L., Yu, S.-Y., Wu, S.-H., & Bao, A.-M. (2016). A sensitive and 
practical RP-HPLC-FLD for determination of the low neuroactive 
amino acid levels in body fluids and its application in depression. 
Neuroscience Letters, 616, 32–37.
Zheleva, A., Nikolova, G., Karamalakova, Y., Hristakieva, E., 
Lavcheva, R., & Gadjeva, V. (2018). Comparative study on some 
oxidative stress parameters in blood of vitiligo patients before and 
after combined therapy. Regulatory Toxicology and Pharmacol-
ogy, 94, 234–239.
Publisher's Note Springer Nature remains neutral with regard to 
jurisdictional claims in published maps and institutional affiliations.
